Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2020-12-07 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Autolus presents additional data on AUTO3
Regulatory Filings Classification · 98% confidence The document is a press release issued via RNS (RNS Number: 8169H) on December 7, 2020. It announces that Syncona's portfolio company, Autolus Therapeutics, presented new clinical data on its product AUTO3 during the ASH Annual Meeting. The text details the data (safety, efficacy, ORR, CR rates) and mentions an upcoming conference call to discuss the results. This structure—announcing results/data presentation from a conference or study, often referencing an attached presentation or call details—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is primarily focused on releasing key financial/clinical performance highlights (data updates) rather than being a comprehensive quarterly report (IR) or a transcript (CT), 'ER' is a strong candidate. However, the document is explicitly distributed via RNS and serves as a general regulatory announcement about clinical progress, which fits the broad 'RNS' category well. Given the content is a clinical data update presented at a medical meeting, which often precedes a formal earnings report, and it is distributed through the RNS system, classifying it as a general Regulatory Filing (RNS) is appropriate, as it is a broad announcement of material information not fitting a more specific category like ER (which usually focuses strictly on financial metrics for a reporting period). Since it is a standard regulatory news service announcement, RNS is the most accurate fallback/general classification.
2020-12-07 English
Autolus presents additional data on AUTO1
Regulatory Filings Classification · 95% confidence The document is a press release issued via RNS (RNS Number: 7278H) on December 7, 2020. It announces that Syncona Limited's portfolio company, Autolus Therapeutics Plc, presented new data on its AUTO1 program during the American Society of Hematology (ASH) Annual Meeting. The text details the clinical data, mentions an upcoming conference call to discuss the data, and includes standard boilerplate information about the companies and the RNS service. This is a typical announcement of clinical trial results and presentation updates, which is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were summarizing periodic results, but since it's focused on specific clinical data presentation, RNS is the most appropriate general regulatory announcement category, as it is not a full report (10-K, IR) or a dedicated management discussion (MDA). Given the context of RNS distribution, RNS is the most fitting general category for this type of market-sensitive announcement that isn't explicitly an ER or DIV.
2020-12-07 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1916 characters) and contains the header 'RNS Number : 8160G' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement titled 'Price Monitoring Extension' regarding an auction call extension for a security. This is a general regulatory announcement that does not fit into specific financial reporting categories like 10-K, ER, or IR. According to Rule 2, since it is a short announcement about a market mechanism update rather than the release of a comprehensive report, and it is clearly sourced from RNS, the most appropriate classification is the general regulatory announcement category.
2020-11-27 English
Half-year Report
Earnings Release Classification · 99% confidence The document explicitly states: 'Syncona Limited... today announces its Interim Results for the six months ended 30 September 2020.' The content details financial performance metrics (Net assets, NAV return) and clinical progress for a six-month period, which is characteristic of an Interim Report. The filing date is November 19, 2020, covering the period ending September 30, 2020. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). Although it is a press release format, the core content is the comprehensive results for the interim period, not just an announcement of the report's publication (RPA). H1 2020
2020-11-19 English
Syncona founds Purespring with a £45m Series A
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 7875F' and is dated '19 November 2020'. It announces a specific corporate action: 'Syncona founds Purespring with a £45m Series A Financing'. This is a material, time-sensitive announcement disseminated via the RNS system, which is the news service of the London Stock Exchange. While it contains detailed information, its primary function is to serve as an official regulatory announcement of a significant event (a new company foundation and financing). Since it is not a full annual report (10-K), an interim report (IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI), and it is clearly an official regulatory news service release, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official announcements not covered by more specific codes. The document length (10,083 chars) is substantial, but the RNS header and footer strongly indicate its nature as a regulatory news service dissemination.
2020-11-19 English
Autolus reports Q3 2020 Financial Results
Earnings Release Classification · 95% confidence The document is an RNS announcement from Syncona Limited, noting that its portfolio company, Autolus Therapeutics Plc, has announced its operational and financial results for the third quarter ended September 30, 2020. The text includes key financial highlights (cash, net loss, EPS for Q3 2020 vs Q3 2019) and details about an upcoming conference call to discuss these results. Since this document is an announcement by a parent/investor (Syncona) about the release of financial results by a portfolio company (Autolus), and it contains the core financial figures and operational updates, it functions as an Earnings Release (ER) for the underlying company, or potentially a Report Publication Announcement (RPA) from the perspective of Syncona reporting on its investment. However, the bulk of the text is the actual content of Autolus's financial results announcement, including the condensed statements of operations. Given the content is the detailed financial summary and operational update, it strongly aligns with an Earnings Release (ER) or an Interim Report (IR). Since it specifically mentions 'Financial Results' and provides the condensed statements for the 'Three Months Ended September 30, 2020', it is best classified as an Earnings Release (ER) which typically precedes the full Interim Report (IR). The document is long enough (over 21k characters) that it is not just a simple RPA. Q3 2020
2020-11-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.